Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Erasme University Hospital
With
University Hospital, Lille
Patients enrolled in this study undergo standard or "random start" ovarian stimulation with Gonadotropins using antagonist protocol before the beginning of chemotherapy. Ovulation is triggered in all patients with a Gonadotropin Releasing Hormone-GnRH agonist.
After retrieval, oocytes are denuded and matured oocytes are subjected to fertilization before embryo freezing or direct vitrification.
Primary objective is to evaluate the efficacy of performing a controlled ovarian stimulation with or without letrozole in young women with newly diagnosed breast cancer who are candidates to receive (neo)adjuvant chemotherapy in terms of mature oocytes collected.
Age
18–40
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of invasive non-metastatic breast cancer (i.e. stage I to III);
Breast cancer diagnosis ≥18 and ≤ 40 years;
No prior history of gonadotoxic treatments;
Fertility preservation counseling for fertility preservation;
Written inform consent;
FSH \< 20 UI/L and/or antra-follicular count ≥ 6 (follicles of 2-9 mm) and/or AMH ≥ 6 pmol (only applicable for patients who undergo controlled ovarian stimulation for embryo/oocyte cryopreservation).
You may not be if
Newly diagnosed stage IV breast cancer (i.e. de novo metastatic breast cancer);
Prior diagnosis of other malignancies before breast cancer.
Clareo Health | Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)
